Stockscreener 앱 받기
1.89
0.53%
0.01
전일 마감가:
$1.88
열려 있는:
$1.86
하루 거래량:
213.97K
Relative Volume:
0.11
시가총액:
$249.54M
수익:
$79,600
순이익/손실:
$-48.26M
주가수익비율:
-3.8399
EPS:
-0.4922
순현금흐름:
$-28.24M
1주 성능:
+4.42%
1개월 성능:
+12.50%
6개월 성능:
+21.15%
1년 성능:
-10.43%
1일 변동 폭
$1.86
$1.92
1주일 범위
$1.63
$1.95
52주 변동 폭
$1.33
$2.365
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.89 | 248.22M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
430.37 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.90 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
792.83 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.20 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
301.20 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 개시 | Ladenburg Thalmann | Buy |
| 2026-01-21 | 개시 | BofA Securities | Buy |
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase Therapeutics (IKT) asks shareholders to add 3M plan shares - Stock Titan
Inhibikase enrolls first patient in phase 3 PAH trial - MSN
Inhibikase Therapeutics (IKT) Stock Trading Today (+7.65%) 2026-04-18Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai
Inhibikase Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat
Inhibikase Enrolls First Patient in Phase 3 PAH Trial - MyChesCo
Inhibikase grants stock options to five new employees - MSN
First patient enrolled in Phase 3 trial of PAH treatment IKT-001 - Pulmonary Hypertension News
MACD Signal: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Grants Stock Options to Five New Employees - MyChesCo
H.C. Wainwright reiterates Inhibikase stock rating on trial progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Inhibikase stock rating on trial progress - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Sahm
Inhibikase Therapeutics Begins Enrollment for PAH Drug Trial - National Today
Inhibikase Therapeutics Enrolls First Patient in Global Phase 3 IMPROVE-PAH Study for Pulmonary Arterial Hypertension Treatment 1 - Minichart
Inhibikase enrolls first patient in Phase 3 PAH drug trial By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (IKT) Begins Key Phase 3 Trial Enrollmen - GuruFocus
Inhibikase Therapeutics Enrolls First Patient In Phase 3 Trial For Pulmonary Arterial Hypertension - marketscreener.com
Inhibikase Begins Pivotal Phase 3 Trial in PAH - TipRanks
Inhibikase enrolls first patient in Phase 3 PAH drug trial - Investing.com
Inhibikase Announces First Patient Enrolled in Global Phase 3 IMPROVE-PAH Trial of IKT-001 - TradingView
First patient dosed in Inhibikase (IKT) global Phase 3 IMPROVE-PAH trial of IKT-001 - Stock Titan
Springer Publishing Company & Cashmere Announce Partnership to Bring Trusted Healthcare Education Content to AI Systems - Weekly Voice
Inhibikase Therapeutics Announces Enrollment of First - GlobeNewswire
Inhibikase grants stock options to new employees under inducement plan - MSN
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Inhibikase Grants Stock Options to New Employees Under Inducement Plan - MyChesCo
IKT Technical Analysis & Stock Price Forecast - Intellectia AI
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Inhibikase Therapeutics Announces Inducement Grants - National Today
Inhibikase Therapeutics Grants Inducement Shares to New Hires - National Today
IKT Stock Analysis: Inhibikase Therapeutics Inc 0.55% dip at $1.8, biotech performance review - Cổng thông tin điện tử tỉnh Tây Ninh
HC Wainwright Has Optimistic Outlook of IKT Q1 Earnings - Defense World
Nocion Therapeutics Appoints Mark Iwicki To Board - citybiz
HC Wainwright Issues Positive Estimate for IKT Earnings - MarketBeat
Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright - The Globe and Mail
H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Death Cross: What is the next catalyst for Inhibikase Therapeutics Inc2026 Update & Safe Capital Investment Plans - baoquankhu1.vn
Inhibikase Therapeutics, Inc. 2025 Annual Report: Pipeline, Intellectual Property, and PAH Drug Development Overview - Minichart
Inhibikase Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Inhibikase Therapeutics 10-K: Operating loss $51.97M, Net loss $48.26M, Interest income $3.72M - TradingView
Inhibikase (NASDAQ: IKT) pivots to PAH drug IKT-001 with Phase 3 trial and $115M raise - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Inhibikase (NASDAQ: IKT) boosts cash as 2025 loss grows and PAH Phase 3 advances - Stock Titan
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
0.66%
자본화:
|
볼륨(24시간):